Roche and Novartis face off in biosimilar drug battle

ZURICH (Reuters) - Switzerland's biggest drugmakers are clashing over cheaper copies of pricey biotech drugs - one reason why Novartis is considering selling its $14 billion stake in cross-town rival Roche.